| Literature DB >> 28962336 |
Leelavinothan Pari1, Asaithambi Karthikeyan1, Paramasivam Karthika1, Ayyasamy Rathinam1.
Abstract
The present study was to evaluate the protective role of hesperidin (HDN) against iron-induced hepatic and renal toxicity in rats. Administration of iron (30 mg/kg body weight) intraperitoneally for 10 days, the levels of serum hepatic markers, renal functional markers, lipid profile, lipid peroxidation markers and iron concentration in blood were significantly (p < 0.05) increased. The toxic effect of iron was also indicated by significant (p < 0.05) decrease in the levels of plasma, liver and kidney of enzymatic and non-enzymatic antioxidants. Administration of hesperidin at different doses (20, 40 and 80 mg/kg body weight) significantly (p < 0.05) reversed the levels of serum hepatic markers, renal functional markers, lipid profile, lipid peroxidation markers, restored the levels of hepatic, renal enzymatic antioxidants and non-enzymatic antioxidants with decrease in iron concentration in blood. Hesperidin at a dose of 80 mg/kg body weight exhibits significant protection on hepatic and renal when compared with other two doses (20 and 40 mg/kg body weight). All these changes were corroborating by histological observations of liver and kidney. This study demonstrated the protective role of hesperidin in reducing toxic effects of iron in experimental rats.Entities:
Keywords: Antioxidant; Hesperidin; Iron; Kidney; Lipid peroxidation; Liver; Oxidative stress
Year: 2014 PMID: 28962336 PMCID: PMC5598436 DOI: 10.1016/j.toxrep.2014.11.003
Source DB: PubMed Journal: Toxicol Rep ISSN: 2214-7500
Fig. 1Structure of hesperidin.
Effect of hesperidin on iron-induced activities of serum hepatic markers in control and experimental rats.
| Groups | Control | Normal + HDN (80 mg/kg) | Normal + Fe (30 mg/kg) | Fe (30 mg/kg) + HDN (20 mg/kg) | Fe (30 mg/kg) + HDN (40 mg/kg) | Fe (30 mg/kg) + HDN (80 mg/kg) |
|---|---|---|---|---|---|---|
| AST (IU/l) | 56.61 ± 4.25a | 57.11 ± 4.51a | 87.70 ± 6.31b | 79.44 ± 6.01c | 72.23 ± 5.59d | 64.02 ± 4.83e |
| ALT (IU/l) | 27.34 ± 2.06a | 28.27 ± 2.62a | 46.61 ± 3.15b | 40.73 ± 2.97c | 35.41 ± 2.75d | 31.79 ± 2.70e |
| ALP (IU/l) | 90.17 ± 8.14a | 91.63 ± 8.08a | 144.31 ± 11.34b | 131.74 ± 11.50c | 119.70 ± 9.96d | 105.51 ± 9.66e |
| LDH (IU/l) | 107.60 ± 8.58a | 107.46 ± 8.60a | 167.65 ± 14.16b | 151.52 ± 11.87c | 136.94 ± 10.63d | 121.36 ± 10.09e |
| GGT (IU/l) | 0.68 ± 0.05a | 0.69 ± 0.05a | 1.21 ± 0.13b | 1.08 ± 0.06c | 0.97 ± 0.06d | 0.83 ± 0.05e |
| Bilirubin (mg/dl) | 0.74 ± 0.06a | 0.72 ± 0.06a | 1.25 ± 0.10b | 1.06 ± 0.09c | 0.94 ± 0.65d | 0.84 ± 0.07e |
Values are mean ± SD for 6 rats in each group. Values are not sharing a common superscript letter (a, b, c, d and e) differ significantly at p < 0.05 (DMRT). HDN—hesperidin, Fe—ferrous sulfate.
Effect of hesperidin on the levels renal functional markers in control and experimental rats.
| Groups | Control | Normal + HDN (80 mg/kg) | Normal + Fe (30 mg/kg) | Fe (30 mg/kg) + HDN (20 mg/kg) | Fe (30 mg/kg) + HDN (40 mg/kg) | Fe (30 mg/kg) + HDN (80 mg/kg) |
|---|---|---|---|---|---|---|
| Urea in serum (mg/dl) | 36.64 ± 2.52a | 35.56 ± 2.45a | 63.41 ± 5.33b | 57.72 ± 4.76c | 51.21 ± 4.89d | 43.54 ± 3.96e |
| Creatinine in serum (mg/dl) | 0.46 ± 0.05a | 0.45 ± 0.05a | 0.92 ± 0.09b | 0.84 ± 0.06c | 0.76 ± 0.04d | 0.55 ± 0.05e |
| Creatinine clearance (ml/min) | 0.29 ± 0.05a | 0.29 ± 0.05a | 0.10 ± 0.03b | 0.14 ± 0.03c | 0.20 ± 0.04d | 0.23 ± 0.04e |
| Hemoglobin (g/dl blood) | 10.90 ± 0.71a | 11.18 ± 0.93a | 6.60 ± 0.63b | 7.70 ± 0.50c | 8.61 ± 0.58d | 10.74 ± 0.65e |
Values are mean ± SD for 6 rats in each group. Values are not sharing a common superscript letter (a, b, c, d and e) differ significantly at p < 0.05 (DMRT). HDN—hesperidin; Fe—ferrous sulfate.
Fig. 2Effect of hesperidin (HDN) on the accumulation of Fe in blood of control and. experimental rats. Values are mean ± SD for 6 rats in each group; values are not sharing a common superscript letter (a, b and c) differ significantly at p < 0.05 (DMRT).
Changes in the levels of Cholesterol, TGs, and PLs in serum and tissues of control and experimental rats.
| Groups | Control | Normal + HDN (80 mg/kg) | Normal + Fe (30 mg/kg) | Fe (30 mg/kg) + HDN (80 mg/kg) |
|---|---|---|---|---|
| Cholesterol | ||||
| Serum | 83.45 ± 8.27a | 82.14 ± 7.81a | 115.97 ± 10.96b | 94.57 ± 8.40c |
| Liver | 281.71 ± 20.16a | 277.77 ± 20.15a | 386.22 ± 30.21b | 312.11 ± 25.78c |
| Kidney | 350.71 ± 27.57a | 347.190 ± 27.06a | 477.91 ± 34.72b | 394.30 ± 32.14c |
| Triglycerides | ||||
| Serum | 73.96 ± 6.59a | 71.17 ± 6.57a | 120.80 ± 10.16b | 85.44 ± 8.13bc |
| Liver | 283.66 ± 16.75a | 280.21 ± 16.10a | 379.78 ± 3.05b | 315.51 ± 22.5c |
| Kidney | 325.11 ± 25.93a | 319.56 ± 25.38a | 466.38 ± 37.85b | 365.83 ± 30.78c |
| Free fatty acids | ||||
| Serum | 77.64 ± 6.43a | 75.74 ± 6.24a | 132.90 ± 13.16b | 89.58 ± 7.47c |
| Liver | 708.42 ± 52.01a | 706.31 ± 51.67a | 871.61 ± 72.67b | 788.37 ± 59.67c |
| Kidney | 325.11 ± 25.93a | 319.56 ± 25.38a | 466.38 ± 37.85b | 365.83 ± 30.78c |
| Phospholipids | ||||
| Serum | 13.92 ± 0.83a | 14.01 ± 0.96a | 7.80 ± 0.94b | 12.57 ± 0.72c |
| Liver | 8.87 ± 1.02a | 9.05 ± 0.92a | 3.87 ± 0.37b | 7.49 ± 0.74c |
| Kidney | 5.29 ± 0.25a | 5.90 ± 0.54a | 1.88 ± 0.65b | 4.49 ± 0.71c |
Values are mean ± SD for 6 rats in each group. Values are not sharing a common superscript letter (a, b and c) differ significantly at p < 0.05 (DMRT). Cholesterol—mg/dl serum and mg/g tissue; triglycerides—mg/dl serum and mg/g tissue; free fatty acids—mg/dl serum and mg/g tissue; phospholipid–mg/dl serum and mg/g tissue. HDN—hesperidin, Fe—ferrous sulfate.
Changes in the levels of TBARS, lipid hydroperoxides in plasma and tissues of control and experimental rats.
| Groups | Control | Normal + HDN (80 mg/kg) | Normal + Fe (30 mg/kg) | Fe (30 mg/kg) + HDN (80 mg/kg) |
|---|---|---|---|---|
| TBARS | ||||
| Plasma | 0.35 ± 0.01a | 0.33 ± 0.01a | 0.46 ± 0.04b | 0.40 ± 0.03c |
| Liver | 8.09 ± 0.64a | 7.56 ± 0.56a | 15.42 ± 1.42b | 9.46 ± 0.78c |
| Kidney | 16.76 ± 1.12a | 16.01 ± 0.90a | 28.41 ± 2.41b | 19.85 ± 1.31c |
| Lipid hydroperoxides | ||||
| Plasma | 13.02 ± 1.38a | 12.85 ± 1.29a | 19.77 ± 2.13b | 15.91 ± 1.68c |
| Liver | 0.83 ± 0.06a | 0.81 ± 0.05a | 1.32 ± 0.08b | 0.96 ± 0.06c |
| Kidney | 0.66 ± 0.05a | 0.64 ± 0.05a | 0.97 ± 0.07b | 0.76 ± 0.06c |
Values are mean ± SD for 6 rats in each group. Values are not sharing a common superscript letter (a, b and c) differ significantly at p < 0.05 (DMRT). The levels of TBARS were expressed as mM/dl plasma and mM/g tissue; Lipid hydroperoxides—×10−5 mM/dl plasma and mM/g tissue. HDN—hesperidin, Fe—ferrous sulfate.
Changes in the activities of enzymatic antioxidants in control and experimental rats.
| Groups | Control | Normal + HDN (80 mg/kg) | Normal + Fe (30 mg/kg) | Fe (30 mg/kg) + HDN (80 mg/kg) |
|---|---|---|---|---|
| SOD | ||||
| Liver | 7.74 ± 0.56a | 8.30 ± 0.81a | 5.45 ± 0.32b | 6.75 ± 0.45c |
| Kidney | 12.07 ± 0.92a | 12.51 ± 1.06a | 8.09 ± 0.56b | 10.41 ± 0.73c |
| CAT | ||||
| Liver | 90.51 ± 6.67a | 94.42 ± 5.92a | 55.04 ± 4.13b | 75.21 ± 5.00c |
| Kidney | 48.25 ± 4.06a | 51.07 ± 4.28a | 32.11 ± 1.91b | 40.34 ± 3.19c |
| GPx | ||||
| Liver | 7.03 ± 0.46a | 7.28 ± 0.49a | 4.61 ± 0.25b | 6.02 ± 0.32c |
| Kidney | 5.46 ± 0.35a | 5.52 ± 0.48a | 3.22 ± 0.16b | 4.76 ± 0.29c |
| GST | ||||
| Liver | 7.98 ± 0.46a | 8.19 ± 0.40a | 5.95 ± 0.26b | 7.08 ± 0.34c |
| Kidney | 6.09 ± 0.34a | 6.15 ± 0.42a | 3.97 ± 0.28b | 5.54 ± 0.28c |
Values are mean ± SD for 6 rats in each group. Values are not sharing a common superscript letter (a, b and c) differ significantly at p < 0.05 (DMRT). SOD–one unit of enzyme activity was taken as the enzyme reaction, which gave 50% inhibition of NBT reduction in one minute/mg protein; CAT—μmol of H2O2 consumed/min/mg protein; GPx—μg of GSH consumed/min/mg protein; GST—μmoles of CDNB-GSH conjugate formed/min/mg protein. HDN—hesperidin, Fe—ferrous sulfate.
Changes in the levels of non-enzymatic antioxidants in control and experimental rats.
| Groups | Control | Normal + HDN (80 mg/kg) | Normal + Fe (30 mg/kg) | Fe (30 mg/kg) + HDN (80 mg/kg) |
|---|---|---|---|---|
| GSH | ||||
| Plasma | 19.93 ± 1.31a | 20.07 ± 1.71a | 15.22 ± 1.19b | 18.07 ± 1.11c |
| Liver | 4.20 ± 0.21a | 4.29 ± 0.30a | 2.83 ± 0.16b | 3.52 ± 0.23c |
| Kidney | 2.44 ± 0.19a | 2.57 ± 0.19a | 1.22 ± 0.18b | 1.77 ± 0.23c |
| Vitamin C | ||||
| Plasma | 1.86 ± 0.08a | 1.94 ± 0.11a | 1.54 ± 0.06b | 1.70 ± 0.07c |
| Liver | 1.59 ± 0.05a | 1.62 ± 0.05a | 1.14 ± 0.04b | 1.44 ± 0.06c |
| Kidney | 0.94 ± 0.08a | 1.01 ± 0.09a | 0.61 ± 0.06b | 0.82 ± 0.07c |
| Vitamin E | ||||
| Plasma | 1.34 ± 0.07a | 1.39 ± 0.12a | 0.90 ± 0.07b | 1.21 ± 0.09c |
| Liver | 0.78 ± 0.06a | 0.83 ± 0.07a | 0.49 ± 0.04b | 0.62 ± 0.05c |
| Kidney | 0.69 ± 0.05a | 0.73 ± 0.05a | 0.46 ± 0.01b | 0.55 ± 0.03c |
Values are mean ± SD for 6 rats in each group. Values are not sharing a common superscript letter (a, b and c) differ significantly at p < 0.05 (DMRT). The level of GSH was expressed as mg/dl plasma and μg/mg tissue protein; The levels of vitamin C and vitamin E were expressed as mg/dl plasma and μM/mg tissue. HDN—hesperidin, Fe—ferrous sulfate.
Fig. 3Histopathology of liver and kidney.